A biotechnology company from Southern Sweden working to develop new pharmaceuticals that can stimulate and inhibit hair growth, is offering licensing agreement to R&D companies working with dermatology.
A Swedish biotechnology company working to develop new pharmaceuticals that can regulate hair growth (by either stimulation or inhibition of hair follicle activity), is offering licensing agreement to R&D companies working within dermatology. The company, founded in 2011, is developing peptide drugs based on proteins found naturally in the body suitable for treatment of both men and women. The lead pharmaceutical peptide is now in a phase I/IIa clinical stage of development. The company's patent strategy and patent portfolio are continuously evaluated and updated. Up to date, the company has patents on the lead drug candidate, as well as patents on several other molecules that control hair growth. The two (2) indications that are the focus of the company are: 1) Stimulating hair growth 2) Inhibiting hair growth In vivo and in vitro studies have confirmed effects in both animals and in human skin after sub-cutaneous application. No signs of toxicity have been observed after administration of repeated dosing up to 3 months. The company is interested in finding partners for licensing agreements. The potential partner should preferably have a strong interest in promoting hair growth regulating products on the market.
Innovations and advantages
The potential benefits of the Swedish company's product have been demonstrated in several preclinical efficacy and safety studies. A clinical study for the regulation of hair growth is currently ongoing at a specialized clinic in Germany. Independent in-vitro and in-vivo studies have shown that: - the lead candidate drug is effective at low concentrations in inhibiting hair growth in human skin, while exhibiting no negative side effects - several pipeline drug candidates stimulated hair growth in mice much faster and produced hair growth over a much larger area than when using a competitors' drug alternative.
Market application codes
05003001 Therapeutic services
05003006 Other therapeutic (including defibrillators)
05005022 Other clinical medicine
05007007 Other medical/health related (not elsewhere classified)
Intellectual property rights
Area of partner's activity
The Swedish company is interested in finding a strategic partner with focus on the dermatological market with a strong interest in research and development of new ground-breaking products with significant value to the patients/users. The company is primarly interested in out-licensing to R&D companies working within dermatology such as pharmaceuticals companies.